IL5RA and Alzheimer disease: Here, we report spontaneous resolution of AD in an adolescent patient participating in the phase 3 CALIMA pivotal trial, which evaluated the safety and efficacy of the anti-IL-5R mAb benralizumab as an add-on therapy for patients with severe, uncontrolled asthma and elevated blood eosinophil counts [7].